{
"id":"mk19_a_gi_q057",
"number":57,
"bookId":"gi",
"correctAnswer":"D",
"title":"Question 57",
"stimulus":[
{
"type":"p",
"hlId":"e739c4",
"children":[
"A 48-year-old man is evaluated for follow-up of cirrhosis due to hepatitis C virus (HCV) infection. He has ascites responsive to furosemide and spironolactone and recent-onset hepatic encephalopathy treated with lactulose. He has a MELD-Na (Model for End-Stage Liver Disease–sodium) score of 12. He takes no additional medications."
]
},
{
"type":"p",
"hlId":"2a962e",
"children":[
"On physical examination, vital signs are normal. Physical examination reveals spider angiomas, abdominal distention, and a palpable liver edge below the right costal margin."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"93eab9",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Prothrombin time",
"children":[
"Prothrombin time"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"78d94d",
"class":"cell text l",
"children":[
"14.6 s"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"c6e520",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Bilirubin, Total, serum",
"children":[
"Total bilirubin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"aea2af",
"class":"cell text l",
"children":[
"2.6 mg/dL (44.5 μmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e8394c",
"class":"cell text l",
"children":[
"0.8 mg/dL (70.7 μmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"57020c",
"class":"cell text l",
"children":[
"HCV DNA"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"fb1fbb",
"class":"cell text l",
"children":[
"600,000 U/mL"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Initiate protease inhibitor–based direct-acting antiviral therapy"
}
},
{
"letter":"B",
"text":{
"__html":"Initiate rifaximin therapy"
}
},
{
"letter":"C",
"text":{
"__html":"Limit dietary protein"
}
},
{
"letter":"D",
"text":{
"__html":"Refer for liver transplantation"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"156d88",
"children":[
"Findings of hepatic decompensation include ascites, jaundice, hepatocellular carcinoma, hepatorenal syndrome, variceal hemorrhage, spontaneous bacterial peritonitis, and hepatic encephalopathy."
]
},
{
"type":"keypoint",
"hlId":"b24a60",
"children":[
"Patients with findings of hepatic decompensation should be referred for consideration of liver transplantation."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"869bf5",
"children":[
"The most appropriate management is referral for liver transplantation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Referral for liver transplantation is indicated in patients whose MELD-Na (Model for End-Stage Liver Disease–sodium) score is 15 or greater and in those with findings of decompensated disease, such as ascites, jaundice, hepatocellular carcinoma, hepatorenal syndrome, variceal hemorrhage, spontaneous bacterial peritonitis, and hepatic encephalopathy. Although the MELD-Na score is used to prioritize patients on the liver transplant list, patients with symptoms of hepatic decompensation should be referred to a liver transplant center for consideration of transplantation. Symptoms of liver decompensation herald a high risk for clinical worsening and a 2-year mortality rate of 50%. The average 1- and 5-year survival rates after liver transplantation are 92% and 75% to 85%, respectively. Therefore, this patient with advancing symptoms of liver decompensation should be considered for liver transplantation, regardless of the MELD-Na score."
]
},
{
"type":"p",
"hlId":"7ec894",
"children":[
"Patients with active hepatitis C virus infection can be considered for antiviral therapy, although the use of protease inhibitors (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") in patients with decompensated cirrhosis has been associated with worsening liver failure. These medications should not be used in patients with advancing symptoms of liver dysfunction. Patients with decompensated cirrhosis should see a hepatologist before treatment and be considered for liver transplantation."
]
},
{
"type":"p",
"hlId":"9b9e80",
"children":[
"The development of hepatic encephalopathy should prompt an evaluation for potential reversible causes. Infections, gastrointestinal bleeding, volume depletion, and medications with sedating properties are common precipitants of hepatic encephalopathy and, if present, should be treated promptly. The initiation of lactulose therapy is appropriate in this setting, but the initiation of rifaximin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") may be limited by cost. Rifaximin does not necessarily need to be added at this time unless lactulose alone does not adequately control symptoms."
]
},
{
"type":"p",
"hlId":"f2f291",
"children":[
"Dietary protein intake was previously thought to be a potential precipitant for hepatic encephalopathy, but this idea has been refuted. Even patients with hepatic encephalopathy should not be given a protein-restricted diet (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
")."
]
}
],
"relatedSection":"mk19_a_gi_s6_13",
"objective":{
"__html":"Treat hepatic failure with liver transplantation."
},
"references":[
[
"Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375:767-77. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27557303",
"target":"_blank"
},
"children":[
"PMID: 27557303"
]
},
" doi:10.1056/NEJMra1504367"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":71,
"B":3,
"C":2,
"D":24,
"E":0
},
"hlIds":[
"e739c4",
"2a962e",
"a462a3",
"93eab9",
"78d94d",
"c6e520",
"aea2af",
"f461b2",
"e8394c",
"57020c",
"fb1fbb",
"cb2b54",
"156d88",
"b24a60",
"869bf5",
"7ec894",
"9b9e80",
"f2f291"
]
}